....
Home
Background
Objectives
What are Microbicides?
MDP 301 Study information
MDP 302 Study information
More MDP Info
Investigator's workshop
MRC website
CTU website
DFID website
Imperial College London
Governance
Clinical Trial Sites
Contacts
Useful Links
Archive
Publications
Policy Briefs


MDP 302 Study Information

18 April 2011

Update on MDP 302


MDP partners in Mozambique, Tanzania, Uganda and Zambia have completed the Top Up study which assessed gel adherence and adherence measurement tools. The clinical research sites are preparing to implement the MDP 302 clinical trial before the end of the year, pending a funding decision. MDP 302 is a randomised, placebo-controlled trial of 1% tenofovir (TFV) vaginal gel which will evaluate the effectiveness of a single dose of tenofovir gel applied prior to sex compared to placebo. It will also assess the relative effectiveness of a single dose compared to the dual dosing (BAT24) that offered 39% protection against HIV infection in the CAPRISA 004 trial. The aim of MDP 302 is to provide information to support implementation post licensure.

The MDP 302 trial will:

  • assess ONE dose of tenofovir vaginal gel per sex act compared to placebo
  • include TWO doses per sex act as we know this provided protection in CAPRISA 004 study populations
  • include 16-17yr olds, and pregnant women (subject to national approvals)
  • include women from Mozambique, Uganda, Tanzania and Zambia – 3 of these countries have no current experience of tenofovir gel
  • reduce the frequency of the clinic visits and tests to get closer to a feasible roll-out schedule


The MDP 302 study design has been through peer review and the updated study design is described on the following documents:


MDP partners in Mozambique, South Africa, Tanzania, Uganda and Zambia are in the latter stages of the Top Up study which is assessing gel adherence and adherence measurement tools. At the end of Top Up the clinical research sites hope to roll over into the MDP 302 clinical trial, but this is subject to funding. MDP 302 design is a randomised, placebo-controlled efficacy trial of 1% tenofovir (TFV) gel which will evaluate the effectiveness of a single dose of tenofovir gel applied prior to sex compared to placebo, as well as the relative effectiveness of a single dose compared to the dual dosing (BAT24) that offered 39% protection against HIV infection in the CAPRISA 004 trial. The aim of MDP 302 is to provide information to support implementation post licensure.

The MDP 302 trial will:

  • assess ONE dose of tenofovir vaginal gel per sex act compared to placebo 
  • include TWO doses per sex act as we know this provided protection in CAPRISA 004 study populations 
  • include 16-17yr olds and women from Mozambique, Uganda, Tanzania and Zambia as well as South Africa – 3 of these countries have no current experience of tenofovir gel
  • reduce the frequency of the clinic visits and tests to get closer to a feasible roll-out schedule 

The following MDP 302 study documents are available:





©2005 MDP | Microbicides Development Programme.....